IL257015B - Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor - Google Patents

Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor

Info

Publication number
IL257015B
IL257015B IL257015A IL25701518A IL257015B IL 257015 B IL257015 B IL 257015B IL 257015 A IL257015 A IL 257015A IL 25701518 A IL25701518 A IL 25701518A IL 257015 B IL257015 B IL 257015B
Authority
IL
Israel
Prior art keywords
inhibitor
pharmaceutical combination
bcl2
mdm2
mdm2 inhibitor
Prior art date
Application number
IL257015A
Other languages
English (en)
Hebrew (he)
Other versions
IL257015A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL257015(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL257015A publication Critical patent/IL257015A/en
Publication of IL257015B publication Critical patent/IL257015B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL257015A 2015-08-28 2018-01-18 Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor IL257015B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562211080P 2015-08-28 2015-08-28
US201562243337P 2015-10-19 2015-10-19
US201562250574P 2015-11-04 2015-11-04
PCT/IB2016/055050 WO2017037579A1 (en) 2015-08-28 2016-08-24 Mdm2 inhibitors and combinations thereof

Publications (2)

Publication Number Publication Date
IL257015A IL257015A (en) 2018-03-29
IL257015B true IL257015B (en) 2022-02-01

Family

ID=56877086

Family Applications (2)

Application Number Title Priority Date Filing Date
IL257015A IL257015B (en) 2015-08-28 2018-01-18 Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor
IL277239A IL277239B (en) 2015-08-28 2020-09-09 mdm2 inhibitors and combinations thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL277239A IL277239B (en) 2015-08-28 2020-09-09 mdm2 inhibitors and combinations thereof

Country Status (11)

Country Link
US (3) US20190060309A1 (cg-RX-API-DMAC7.html)
EP (2) EP4241850A3 (cg-RX-API-DMAC7.html)
JP (2) JP2018528206A (cg-RX-API-DMAC7.html)
KR (1) KR20180041677A (cg-RX-API-DMAC7.html)
CN (2) CN111821306A (cg-RX-API-DMAC7.html)
AU (2) AU2016314082B2 (cg-RX-API-DMAC7.html)
CA (1) CA2992221C (cg-RX-API-DMAC7.html)
ES (1) ES2962460T3 (cg-RX-API-DMAC7.html)
IL (2) IL257015B (cg-RX-API-DMAC7.html)
RU (2) RU2020142739A (cg-RX-API-DMAC7.html)
WO (1) WO2017037579A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2018075823A1 (en) 2016-10-19 2018-04-26 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11285154B2 (en) 2017-03-29 2022-03-29 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
AU2018242612B2 (en) * 2017-03-31 2020-05-21 Novartis Ag Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors
WO2019040511A1 (en) * 2017-08-22 2019-02-28 University Of Maryland Batimore DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS
JP2020536855A (ja) * 2017-09-26 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
EP3694518A1 (en) * 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
WO2019133992A1 (en) * 2017-12-31 2019-07-04 Evergreen Biosciences Compositions for cryopreservation and methods of use thereof
WO2019174576A1 (zh) * 2018-03-12 2019-09-19 罗欣药业(上海)有限公司 咪唑并吡咯酮化合物及其应用
TWI791794B (zh) * 2018-03-20 2023-02-11 瑞士商諾華公司 藥物組合
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
JP7058345B2 (ja) * 2018-07-31 2022-04-21 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
MX2020009759A (es) 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
WO2020024834A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
KR20210106484A (ko) 2018-12-20 2021-08-30 노파르티스 아게 Hdm2-p53 상호작용 억제제와 bcl2 억제제의 조합 및 암 치료를 위한 이의 용도
WO2021018032A1 (en) * 2019-07-26 2021-02-04 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
US12343352B2 (en) 2019-12-03 2025-07-01 Ascentage Pharma (Suzhou) Co., Ltd. N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
TW202200147A (zh) * 2020-05-26 2022-01-01 韓商韓美藥品股份有限公司 Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
JP2024157057A (ja) * 2021-06-29 2024-11-07 国立大学法人 東京大学 バレット食道の治療用組成物
CN117562907B (zh) * 2023-11-17 2025-08-22 广州医科大学 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU2503A (sh) 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
EP2361905B1 (en) 2005-05-18 2013-03-06 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2370566A1 (en) * 2008-12-03 2011-10-05 Università Degli Studi Di Torino Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8859535B2 (en) * 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US20140348819A1 (en) * 2011-06-24 2014-11-27 Dana-Farber Cancer Institute, Inc. Methods of Treating Cancer
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
EP2752191A1 (en) * 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
DK3068393T5 (da) * 2013-11-11 2022-08-22 Amgen Inc Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer
WO2015084804A1 (en) * 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
KR20160100975A (ko) 2013-12-23 2016-08-24 노파르티스 아게 제약 조합물

Also Published As

Publication number Publication date
RU2020142739A (ru) 2021-01-15
CA2992221A1 (en) 2017-03-09
AU2016314082A1 (en) 2018-02-08
RU2018110770A3 (cg-RX-API-DMAC7.html) 2020-01-15
EP4241850A2 (en) 2023-09-13
AU2019204938A1 (en) 2019-07-25
IL277239A (en) 2020-10-29
RU2740091C2 (ru) 2021-01-11
IL257015A (en) 2018-03-29
AU2016314082B2 (en) 2019-07-25
WO2017037579A1 (en) 2017-03-09
CN108348520A (zh) 2018-07-31
US20230398115A1 (en) 2023-12-14
IL277239B (en) 2022-04-01
US20190060309A1 (en) 2019-02-28
RU2018110770A (ru) 2019-09-30
EP3340989B1 (en) 2023-08-16
CN111821306A (zh) 2020-10-27
JP2021042222A (ja) 2021-03-18
CA2992221C (en) 2023-06-27
JP2018528206A (ja) 2018-09-27
ES2962460T3 (es) 2024-03-19
KR20180041677A (ko) 2018-04-24
RU2020142739A3 (cg-RX-API-DMAC7.html) 2021-05-20
EP4241850A3 (en) 2023-11-08
AU2019204938B2 (en) 2020-07-16
EP3340989A1 (en) 2018-07-04
US20210260059A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
IL257015B (en) Pharmaceutical combination of 2mdm inhibitor and 2bcl inhibitor
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL267291A (en) Actonucleotidase inhibitors and methods of using them
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
HUE062460T2 (hu) TRPC6 inhibitorok
IL259796A (en) Aza-benzimidazole inhibitors of pad4
IL282482A (en) Variants of protoxin-II and methods of use
SG11201708034SA (en) Methods of administering glutaminase inhibitors
PT3487505T (pt) Administração e dosagem de diaminofenotiazinas
LT3532459T (lt) Lsd1 inhibitoriai ir jų medicininis panaudojimas
IL282508A (en) Variants of protoxin-II and methods of use
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
PT3319609T (pt) Composições e métodos de uso de combinações de fármacos antibacterianos
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201413530D0 (en) Treatment and prevention of malaria
PT3397364T (pt) Elementos estruturados e métodos de utilização
PT3348547T (pt) Derivados de benzimidazole como inibidores de nav 1.7 (canal de sódio, controlado por tensão, tipo ix, subunidade alfa (scn9a)) para o tratamento de dor, disúria e esclerose múltipla
PL3081228T3 (pl) Iryzyna do leczenia i zapobiegania osteoporozie
PT3503885T (pt) Composição farmacêutica e métodos de utilização
IL252752A0 (en) Pharmaceutical preparations containing a combination of pyridazine and egfr inhibitor
IL252424A0 (en) Treatment of multiple sclerosis with a combination of laquinimod and a statin
SI3173075T1 (sl) Farmacevtski kombinacijski pripravek inhibitorja ACE in diuretika zanke
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
AU2015902765A0 (en) Novel aminopeptidase inhibitors and methods of use